Overview of Sominex

Quick Facts

Property	Description
Active ingredient	Eszopiclone
Form	Oral Tablet
Pharmacological class	Nonbenzodiazepine Hypnotic (Z-drug)
Common use	Facilitating sleep onset and maintenance
Origin	Synthetic S-stereoisomer

Sominex (Eszopiclone): A Prescription Sedative-Hypnotic

Sominex, when referencing the active ingredient Eszopiclone, is a prescription-only synthetic drug classified as a Nonbenzodiazepine Hypnotic agent. This medication belongs to the class of sedative-hypnotics, often referred to as Z-drugs, which are chemically synthesized for the management of sleep disorders. Its status as a prescription drug highlights its controlled distribution, intended for supervised patient use.

Eszopiclone is administered via the oral route as a single-ingredient Oral Tablet, a form designed for convenient ingestion. Its positioning as a nonbenzodiazepine distinguishes it from older compounds through its unique binding profile to the central nervous system's inhibitory receptors.

Understanding the Active Ingredient and Chemical Type

The core compound is Eszopiclone, which is the sole active ingredient and is designated as the pure S-stereoisomer of zopiclone. The tablet is composed of the active Eszopiclone alongside basic solid excipients. This synthetic compound's purity ensures a consistent effect, making it a reliable tool in the therapeutic options for insomnia.

General Purpose: Facilitating Sleep Initiation and Maintenance

The general purpose of this medication is to specifically assist individuals who experience both difficulty falling asleep and difficulty remaining asleep. It works by modulating GABA-A receptor complexes to enhance the brain's natural inhibitory signals, thereby promoting a restful state. This pharmacological modulation facilitates the ability to reduce sleep onset latency and to improve sleep maintenance by reducing awakenings throughout the night.

What side effects are possible with Sominex?

Eszopiclone is associated with a distinct profile of adverse reactions and safety constraints documented in official government labeling. The adverse effects are formally categorized by frequency and the body system affected, reflecting how regulatory authorities communicate risks.

Adverse Reactions and Common Effects

The most commonly observed effects, those occurring in two percent or more of patients in clinical trials, often involve the nervous and gastrointestinal systems. These include an unpleasant taste (dysgeusia), headache, somnolence (drowsiness), dizziness, dry mouth, and nausea. Other common events include rash and viral or respiratory infections.

Serious Documented Safety Risks

Official labeling carries a warning regarding Complex Sleep Behaviors. These activities, such as sleep-driving or making phone calls while not fully awake, have resulted in serious injury and death. Eszopiclone is also associated with rare but severe Anaphylactic and Anaphylactoid Reactions, including angioedema of the throat, which may obstruct the airway. The drug is contraindicated in patients who have a known history of these complex behaviors or hypersensitivity to the medicine. Additionally, the label notes the potential for worsening of depression or the emergence of suicidal thinking.

Population and Contextual Safety Notes

Safety is influenced by patient group and duration of use. Older adults may be more susceptible to CNS depressant effects, raising the risk of falls. For individuals with severe hepatic impairment, a specific maximum dose is required. The potential for next-day impairment and the occurrence of rebound insomnia upon rapid discontinuation are documented exposure-related safety patterns.

Overdose and Emergency Response

Overdose of Sominex (Eszopiclone) results in a general exaggeration of the drug’s pharmacological properties, leading to symptoms of central nervous system (CNS) depression.

Documented Overdose Manifestations

Signs of overdosage include pronounced somnolence (unusual sleepiness), significant mental status changes, and progression to a change or loss of consciousness. More severe presentations involve respiratory depression, characterized by difficult, troubled, or shallow breathing. This can lead to critical signs such as pale or blue lips, fingernails, or skin, and may progress to coma. Regulatory documents note that fatalities have been reported only in cases where Eszopiclone was combined with alcohol or other CNS depressant drugs.

When Immediate Medical Help is Required

Any suspected overdose requires immediate medical attention. Regulators explicitly mandate calling emergency services if the individual has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. Contacting a Poison Control center is also advised.

Officially Described Management Measures

Management is generally supportive and focuses on closely monitoring vital signs. Procedural interventions described in official labeling include gastric lavage (stomach washout) and administration of activated charcoal. The compound Flumazenil, a GABA A receptor antagonist, is documented as a treatment option that may be used to reverse the sedative effects of overdosage. The possibility of a mixed-drug overdose must be considered during treatment.

Therapeutic Uses of Sominex

What Sominex (Eszopiclone) treats: main uses and benefits

Eszopiclone may be part of symptomatic management for groups of sleep symptoms that often occur together, specifically impaired sleep initiation (difficulty falling asleep) and disrupted sleep maintenance (frequent nocturnal awakenings). It is applied in clinical contexts marked by persistent, significant sleep deficits, used in areas where short-term symptom management is appropriate, and may assist with easing the overall symptom load.

This medication is considered relevant for easing symptoms in cases of chronic insomnia, where sleep disturbance is prolonged, and is applied across domains where additional symptomatic support is needed in co-morbid insomnia. These indications involve conditions characterized by periods of heightened symptoms that interfere with daily comfort. The symptomatic relief generally helps with managing symptoms that interfere with daily comfort.

Therapeutic Focus: Insomnia Symptoms
Primary Focus	Symptomatic relief for difficulty falling and staying asleep.
Common Use Context	Chronic or co-morbid sleep disorders causing functional strain.
Main Therapeutic Benefit	Assists with maintaining functional stability through symptomatic relief.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Rules

This medication is officially approved for use in adults (18 years and older) who experience chronic insomnia, but regulatory documentation establishes clear rules for non-eligibility and conditional use.

Classification	Eligible Population	Restriction/Exclusion Condition
Allowed	Adults (18 years and older)	Use is restricted for elderly adults (ge 65 years) and debilitated patients.
Not Recommended	Pediatric patients (under 18)	Safety and effectiveness have not been established in this age group.

Absolute Contraindications

Official labeling mandates that Eszopiclone must not be used by patients who have a known hypersensitivity to the drug or who have previously experienced an episode of a complex sleep behavior (such as sleep-driving or sleep-walking) after taking Eszopiclone, zaleplon, or zolpidem. Some regions also cite severe hepatic insufficiency and severe respiratory impairment as absolute contraindications.

Conditional and Restricted Use

The medicine is permitted but requires dose restriction for elderly patients and those with severe hepatic impairment due to altered drug clearance and increased sensitivity. Patients with a history of alcohol or drug abuse or those with underlying depression must use the medicine with caution as specified in government product monographs.

Pregnancy and Lactation Status

Available human data on use during pregnancy is insufficient to determine drug-associated risk. It is not known if Eszopiclone is excreted into human milk during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Eszopiclone documents interactions primarily through metabolic and pharmacodynamic mechanisms. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) labels describe potential interactions with specific drug classes and substances.

Key Interaction Constraints

Interaction Type	Interacting Substance/Class	Official Regulatory Statement
Pharmacokinetic	Potent CYP3A4 Inhibitors (e.g., Ketoconazole)	Co-administration leads to increased Eszopiclone exposure (e.g., 2.2-fold increase in AUC).
	Potent CYP3A4 Inducers (e.g., Rifampicin)	Expected to reduce Eszopiclone systemic exposure and subsequent efficacy.
Pharmacodynamic	CNS Depressants (e.g., Opioids, Antipsychotics, Alcohol)	Results in additive CNS depression and enhanced psychomotor impairment.

Administration and Population Restrictions

Co-administration with potent CYP3A4 inhibitors is formally contraindicated in elderly patients (aged over 65 years). For patients with severe hepatic impairment, a dose restriction is required due to reduced clearance, which is a consequence of impaired metabolism. The regulatory labels advise against concomitant use with Alcohol (Ethanol) due to pronounced additive effects. Furthermore, the label notes that taking Eszopiclone with or immediately following a high-fat/heavy meal may reduce the effect on sleep onset by delaying absorption. A timing-based constraint requires a commitment to 7 to 8 hours of uninterrupted sleep remaining to minimize next-day impairment.

Mechanism of Action

Selective Modulation of the GABA-A Receptor

Eszopiclone functions as a Positive Allosteric Modulator (PAM), targeting the GABA-A receptor complex in the central nervous system (CNS), with high selectivity for subtypes containing the alpha1 subunit. By enhancing the receptor's response to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), the drug acts to amplify the brain's natural inhibitory signals, directly modulating the pathways involved in the regulation of wakefulness and arousal.

Promoting Cellular Hyperpolarization

The increased binding efficiency of GABA, due to Eszopiclone's action, causes the ion channel linked to the receptor to open more readily, leading to a surge of negatively charged Chloride ( Cl^-) ions into the neuron. This cellular event results in hyperpolarization, which stabilizes the neuron and drastically reduces its ability to fire. This physiological quieting of neuronal activity is the systemic shift that defines the central inhibitory state.

GABA-Dependent Mechanism and Constraints

Eszopiclone's entire mechanism is GABA-dependent; it only enhances existing inhibition and cannot initiate an effect in the absence of the native neurotransmitter. The mechanism can experience pharmacodynamic tolerance with prolonged use, resulting from adaptive changes in the GABA-A receptor complex that constrain the drug's effectiveness over time. The continuous inhibitory modulation sustains the state of neural quieting.

Dosage and Administration Information

Official Administration Guidelines for Eszopiclone

Eszopiclone is an oral tablet indicated for the treatment of insomnia. The proper use of this medicine involves specific parameters to ensure controlled absorption and minimize next-day impairment.

Dosage and Timing

Patient Group	Recommended Starting Dose	Maximum Total Dose	Timing Rule
Non-Elderly Adults	1 mg once daily	3 mg once daily	Immediately before bedtime
Elderly / Debilitated Patients	1 mg once daily	2 mg once daily	Immediately before bedtime

Administration Conditions and Restrictions

Condition	Instruction
Route of Administration	Oral. Swallow the film-coated tablet whole.
Food Intake	Do not take with or immediately after a heavy, high-fat meal. This condition is crucial as food slows the drug's absorption and may reduce its effect on sleep onset.
Sleep Duration Constraint	Only take the dose if you are able to get a full night's sleep (7 to 8 hours) before your planned time of awakening.

Special Population Rules

For patients with severe hepatic impairment or those taking potent CYP3A4 inhibitors, the total dose of Eszopiclone should not exceed 2 mg once daily. No dosage adjustment is generally considered necessary for patients with renal impairment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Sominex (Eszopiclone)

This section summarizes the structure of the available research on Eszopiclone, focusing strictly on what was studied and what patterns the research describes, without stating or implying any therapeutic effects or clinical guidance.

Evidence for Use in Primary Insomnia

The core evidence for Eszopiclone comes from short-term (up to 6 weeks) and intermediate-term (up to 6 months) Randomized Controlled Trials (RCTs) against placebo in adults with chronic primary insomnia. These studies research examined sleep using both objective Polysomnography (PSG) and patient-reported experiences via daily diaries. When comparing the compound group to placebo, findings describe patterns observed in the studies where shorter times to fall asleep and longer total sleep times were observed as group differences. Research also explores short-term symptom changes in individuals with insomnia occurring alongside other conditions, such as chronic pain or major depressive disorder, where the compound was evaluated in trials as an adjunctive treatment.

Long-Term Evidence and Special Populations

Dedicated studies monitored the use of the compound continuously for up to six months. During these longer follow-up periods, researchers relied heavily on patient-reported outcomes describing perceived discomfort and sleep quality, as objective PSG data evidence is limited beyond the initial few weeks. Research has explored use in older adults (aged 65 and above), where dedicated RCTs describe patterns in sleep outcomes similar to those documented in younger adult populations.

It is important to note that data for certain groups remain insufficient. For instance, comprehensive research on the use of Eszopiclone in children and adolescents evidence is limited, and research regarding pregnant or breastfeeding individuals is not fully characterized.

Research Gaps and Remaining Uncertainties

The research landscape presents several limitations. Comparative evidence is lacking from large-scale studies directly comparing Eszopiclone against established non-pharmacological therapies or older hypnotics over extended periods. Data that characterize outcomes such as psychological or physical dependence or potential withdrawal effects following continuous use exceeding the documented six-month period remain insufficient.

Study results reflect the specific conditions under which they were conducted and results apply only to the populations studied. Research provides context but not individual predictions, as findings describe group patterns.

Key Studies & References A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder (ClinicalTrials.gov ID: NCT00368030)

Frequently Asked Questions (FAQ)

Common questions about Sominex (Eszopiclone) (FAQ)

Q: Is Sominex the same thing as Lunesta?

A: Yes, Eszopiclone is the active ingredient's generic name. Lunesta is one of the brand names under which this drug is marketed and officially approved in the United States and other regions.

Q: How long does it usually take for Sominex to start working?

A: Official information advises that the drug is designed to work quickly, which is why it must be taken immediately before bed. Taking it with or right after a heavy, high-fat meal can actually delay the time it takes for the drug to start working, which may reduce its intended effect.

Q: What is the 'next-day' grogginess people talk about with Sominex?

A: Regulatory documents refer to this as Next-Day Impairment or somnolence (drowsiness). This is a known risk and a safety warning, indicating that even if a person feels awake, residual drug effects may still affect alertness and coordination the following day.

Q: Can you take Sominex if you only get a few hours of sleep?

A: The official administration instructions are strict: the drug should only be taken if you have enough time for a full night's sleep, typically defined as 7 to 8 hours of uninterrupted time remaining. Taking it when you will get fewer hours of sleep may lead to a higher chance of next-day impairment.

Q: Is Sominex addictive?

A: The US Drug Enforcement Administration (DEA) classifies Eszopiclone as a Schedule IV controlled substance. This classification indicates that the drug carries a potential risk for misuse, abuse, and the development of physical and psychological dependence.

Q: Can Sominex cause strange dreams or nightmares?

A: Yes, official prescribing information lists unusual dreams and abnormal dreams as documented adverse reactions. If you experience these effects, they are noted in the drug's safety profile.

Q: Do you have to stop taking Sominex gradually?

A: Official documents note that stopping the medication abruptly may lead to the return of insomnia at a worse level (rebound insomnia) or potential withdrawal symptoms. Official information notes that a healthcare provider may suggest a gradual decrease in the dose to stop taking the drug.

Q: Can you drive the day after taking Sominex?

A: Regulatory warnings note that driving or engaging in activities that require complete mental alertness the day after use is not recommended, particularly for those taking the higher 2 mg and 3 mg doses, due to the risk of residual drug effects.

Q: Is it common to have a metallic or bitter taste after taking Eszopiclone?

A: Yes, an unpleasant taste (scientifically called dysgeusia), often described as metallic or bitter, is one of the most commonly reported adverse reactions in clinical trials for the drug.

Q: How is Eszopiclone different from zolpidem (Ambien)?

A: Both drugs are classified as Nonbenzodiazepine Sedative-Hypnotics (Z-drugs) approved for treating insomnia. Official information notes that Eszopiclone is approved for use in both sleep onset and sleep maintenance, meaning it can help with falling asleep and staying asleep, whereas Zolpidem's uses can vary by formulation.

Q: Can older adults use Sominex safely?

A: Official labeling permits use in older adults but the official label requires a lower maximum dose (2 mg) compared to younger adults. This is due to slower clearance and increased susceptibility to Central Nervous System (CNS) depressant effects, which raises the risk of falls.

Q: Does Eszopiclone lose effectiveness over time?

A: Regulatory documents acknowledge the potential for pharmacodynamic tolerance with prolonged use. This describes a mechanism where the body may adapt to the drug, potentially causing its effectiveness to lessen over time.

Q: Can certain herbal supplements interact with Eszopiclone?

A: The potential for drug-drug interactions is primarily described via the CYP3A4 metabolic pathway and the additive effects of CNS depressants. Any herbal supplement known to affect these pathways could potentially interact with Eszopiclone.

Q: What research shows Sominex helps with chronic insomnia?

A: The drug's approval is supported by clinical trials, some of which lasted up to six months, in adults with chronic insomnia. These studies observed that the group taking Eszopiclone experienced patterns of decreased time to fall asleep and improved total sleep time compared to the placebo group.

Q: Is it okay to take Sominex every night?

A: The drug is indicated for the treatment of insomnia, and official clinical trials supporting its use included evaluation of continuous, nightly administration for up to 6 months.

Q: Do you have to take Sominex on an empty stomach?

A: Official instructions advise not taking it with or immediately following a heavy, high-fat meal. This is because food can slow down the drug's absorption. Taking it on a relatively empty stomach helps ensure the fastest possible onset of effect.

Q: Is Sominex used for anxiety-related sleep issues?

A: The drug is officially indicated only for the treatment of insomnia. While insomnia can occur alongside other conditions, such as anxiety, the regulatory approval specifically targets the symptom of difficulty with sleep.

Q: Are there different forms of Sominex available?

A: Eszopiclone is typically available as a single-ingredient oral film-coated tablet in multiple dosage strengths. No other dosage forms, such as liquids or extended-release capsules, are generally available.

Q: Does Eszopiclone affect appetite or weight?

A: Official product labeling lists both weight gain and weight loss as documented but uncommon adverse reactions reported in clinical trials.

Q: What is the maximum duration of use described in prescribing information?

A: The longest duration of continuous use evaluated in the key clinical trials that supported the drug's approval was 6 months. The US FDA label does not set a formal, mandatory restriction on the maximum duration of use for all patients.

Q: What kind of research has been done on Sominex in children or teenagers?

A: The official product label clearly states that the safety and effectiveness have not been established in pediatric patients, which includes children and adolescents under 18 years of age.

How should Sominex be stored and disposed of?

Storage and Disposal Requirements for Eszopiclone

Eszopiclone tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions [1]. The medication must be kept in its original container, tightly closed, and stored away from excess heat, moisture, and must be kept from freezing [2].

As a controlled substance, Eszopiclone must be kept out of the sight and reach of children and stored in a safe place to prevent misuse [3]. For disposal, the preferred method is a drug take-back program [4]. If a program is unavailable, tablets must be mixed with an undesirable substance (e.g., coffee grounds) and sealed in a container before being placed in household trash [4].

Official Regulatory Sources

[LUNESTA™ (eszopiclone) TABLETS 1 mg, 2 mg, 3 mg - accessdata.fda.gov]
[LUNESTA- eszopiclone tablet, coated - DailyMed]
[Eszopiclone: MedlinePlus Drug Information]
[Where and How to Dispose of Unused Medicines - FDA]

Sominex